期刊
CURRENT MEDICINAL CHEMISTRY
卷 17, 期 10, 页码 929-956出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/092986710790820660
关键词
Malaria; electron transport chain; mitochondria; bc(1) complex; dihydroorotate dehydrogenase; succinate dehydrogenase; type II NADH dehydrogenase
资金
- Fundacao para a Ciencia e Tecnologia (FCT, Portugal) [PTDC/SAU-FCF/098734/2008]
- FCT [SFRH/BD/30689/2006]
- Fundação para a Ciência e a Tecnologia [SFRH/BD/30689/2006, PTDC/SAU-FCF/098734/2008] Funding Source: FCT
Malaria is a major worldwide public health threat with worrying social and economic burdens due to the rapid emergence of multidrug-resistant Plasmodium falciparum strains. As a result, there is an urgent need to find novel drugs that might overcome clinical resistance to marketed antimalarials. In recent years, the mitochondrial electron transport chain (mtETC) has been explored for the development of new antimalarials. Type II NADH: quinone oxidoreductase (PfNDH2), succinate dehydrogenase (SDH) and cytochrome bc(1) have become a major focus of those efforts, leading to several studies of its biochemistry and the design of potent inhibitors. Furthermore, de novo pyrimidine biosynthesis in malaria parasites, particularly dihydroorotate dehydrogenase (PfDHODH), is also receiving increasing attention. The enzymes involved in the mtETC are valuable targets in malaria chemotherapy, not only because they play a critical role in metabolic pathways of P. falciparum, but also because they differ significantly from the analogous mammalian system. Inhibition of such enzymes results in the shutdown of mitochondrial electron flow, leading to the arrest of pyrimidine biosynthesis and consequent parasite death. In this review, we aim to outline recent advances in the inhibition of mitochondrial metabolic pathways, highlighting the major classes of known inhibitors and those that are currently being developed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据